Azoximer bromide
 | |
| Systematic (IUPAC) name | |
|---|---|
| Poly[[1-(carboxymethyl)piperazin-1-ium-1,4-diyl bromide]ethylene- co-[(piperazin-1,4-diyl 1-oxide)ethylene]] | |
| Clinical data | |
| Pharmacokinetic data | |
| Bioavailability | up to 89% |
| Half-life | 25.4 hours (intravenous routes) |
| Identifiers | |
| 892497-01-7 | |
| L03AX | |
| Synonyms | Polyoxidonium, Synpol |
| Chemical data | |
| Formula | [[C8H15BrN2O2]x[C6H12N2O]y]n |
| 60000–100000 g/mol | |
Azoximer bromide is a macromolecular compound with high-molecular weight and high immunomodulating activity. It is for treatment and prophylaxis of diseases connected with damage of immune system. It is a N-oxidized polyethylene–piperazine derivative.
Azoximer bromide is registered in US Patent-5503830 from 1996,[1][2][3] in the Russian Federation from 1996, under registration number 96/302/9, FS 42-3906-00.[4]
References
- ↑ http://www.google.com/patents/about?id=s9cfAAAAEBAJ&dq=US+5503830
- ↑ http://www.wikipatents.com/US-Patent-5503830/compounds-having-immunostimulating-activity-and-methods-of-use-thereof
- ↑ http://www.freepatentsonline.com/EP0789586.html
- ↑ State Scientific Centre of Russian federation, Immunological Institute of Russian Federation Health Resort, CLINICAL ASPECTS OF USE OF IMMUNOMODULATOR POLYOXIDONIUM, Methodical handbook for doctors issued by State Scientific Centre of Russian Federation – Immunological Institute of Russian Federation Health Resort Moscow – 2003